Finance

Lists
Why is 300357 up 3.85%?
Dive Deeper
300357:SHE
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
CNÂ¥22.38
+3.85%
(+0.83) 1D
Nov 4, 3:04:01 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 300357...
Open
CNÂ¥21.49
High
CNÂ¥22.77
Low
CNÂ¥21.40
Mkt. cap
11.28B
Avg. vol.
7.84M
Volume
18.87M
P/E ratio
27.42
52-wk high
CNÂ¥34.96
52-wk low
CNÂ¥18.48
EPS
CNÂ¥0.82
Shares outstanding
523.58M
No. of employees
2K
Open
CNÂ¥21.49
High
CNÂ¥22.77
Low
CNÂ¥21.40
Mkt. cap
11.28B
Avg. vol.
7.84M
Volume
18.87M
P/E ratio
27.42
52-wk high
CNÂ¥34.96
52-wk low
CNÂ¥18.48
EPS
CNÂ¥0.82
Shares outstanding
523.58M
No. of employees
2K
News stories
From web sources and news partners
About Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
CEO-
Employees1.81K
FoundedSep 19, 2002
Headquarters-
SectorPharmaceutical industry
Industry-
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
209.04M
252.84M
261.32M
395.83M
Cost of goods sold
11.11M
12.02M
12.18M
17.88M
Cost of revenue
11.11M
12.02M
12.18M
17.88M
Research and development expenses
31.40M
24.91M
22.99M
23.46M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
128.79M
117.09M
118.40M
139.81M
Operating expense
160.79M
143.93M
143.60M
173.80M
Total operating expenses
171.90M
155.95M
155.79M
191.68M
Operating income
37.15M
96.89M
105.54M
204.15M
Other non operating income
-246.72K
-24.48K
-175.66K
125.88K
EBT including unusual items
38.43M
131.78M
108.66M
206.21M
EBT excluding unusual items
41.38M
131.03M
109.00M
205.95M
Income tax expense
5.57M
15.27M
16.59M
31.07M
Effective tax rate
14.51%
11.59%
15.27%
15.07%
Other operating expenses
5.99M
-2.31M
3.23M
4.96M
Net income
36.07M
119.23M
94.22M
177.84M
Net profit margin
17.26%
47.16%
36.05%
44.93%
Earnings per share
-
-
-
-
Interest and investment income
4.67M
34.39M
3.81M
1.85M
Interest expense
-196.48K
-233.08K
-172.40K
-184.38K
Net interest expenses
4.48M
34.16M
3.64M
1.67M
Depreciation and amortization charges
-
-
-
-
EBITDA
49.60M
109.35M
119.27M
216.61M
Gain or loss from assets sale
-630.07K
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps